Purpose of review <p>Herpes zoster (HZ), or shingles, is caused by reactivation of varicella-zoster virus (VZV), the virus responsible for chickenpox. We aim to characterize the global landscape of national vaccination recommendations for the use of recombinant zoster vaccine (RZV; Shingrix^®, GSK).</p> Recent findings <p>A recent systematic review found a cumulative incidence of HZ among adults aged ≥ 50 years of 2.9–19.5 cases per 1,000 individuals. In 2017, the US and Canada authorized Shingrix for this age group. Shingrix has now been approved for use in dozens of countries.</p> Summary <p>We identified information about Shingrix national vaccination recommendations in 30 of 52 countries (58%) where publicly available evidence confirmed Shingrix has been approved. All 30 countries recommend vaccination based on age. Individuals with underlying conditions that increase their HZ risk were also recommended for vaccination in 24 (80%) countries. This study provides the first comprehensive overview of the complex global landscape of national vaccination policies for recombinant zoster vaccine.</p>